Last updated: February 21, 2026
What is NDC 65162-0750?
NDC 65162-0750 refers to a specific pharmaceutical product listed in the National Drug Code directory. Based on available data, this NDC corresponds to Bupivacaine Hydrochloride Injectable Solution, used for local anesthesia.
Market Size and Demand Drivers
Global Market Value
The anesthetic drugs market, including local anesthetics like Bupivacaine, was valued at approximately $3.8 billion in 2022.[1] Projected annual growth compounds at an average rate of 5-7% through 2028, driven by increasing surgical procedures and rising adoption in outpatient settings.
Regional Market Distribution
| Region |
Market Share |
Growth Rate (2022-2028) |
Key Drivers |
| North America |
45% |
6% |
High surgical volume, aging population |
| Europe |
25% |
5.5% |
Healthcare infrastructure, regulatory access |
| Asia-Pacific |
20% |
7% |
Expanding healthcare coverage, population growth |
| Middle East & Africa |
10% |
4% |
Increasing elective procedures |
Competitive Landscape
Leading manufacturers include Hospira, Hikma, and Teva. The market features both innovator and generic competitors, with generics capturing an estimated 70% of volume.[2]
Price Dynamics and Projections
Current Pricing Overview (2023)
| Packaging Type |
Price per vial (USD) |
Volume (units) |
Estimated Annual Revenue |
| 10 mL single-dose vial |
$15-$20 |
1 million |
$15-$20 million |
| 50 mL multi-dose vial (multi-use) |
$60-$85 |
300,000 |
$18-$25.5 million |
Factors Influencing Price
- Manufacturing costs: Increasing raw material prices raise production costs.
- Regulatory status: FDA approval status influences pricing power.
- Market competition: The presence of generics drives prices downward.
- Supply chain dynamics: Disruptions can lead to price volatility.
Future Price Projections (2024-2028)
| Year |
Estimated Price Range (USD) per vial |
Notes |
| 2024 |
$13-$19 |
Competitive pressures persist, slight decline ongoing |
| 2025 |
$12-$18 |
Possible price stabilization or slight decrease |
| 2026 |
$11-$17 |
Entry of new generic competitors possibly reduces prices |
| 2027 |
$10-$16 |
Demand stabilizes, pricing maintains or slightly drops |
| 2028 |
$10-$15 |
Market volume growth offsets some price declines |
Regulatory and Reimbursement Environment
FDA Status
- Approved for hospital and outpatient use.
- No recent patent protections; exclusivity for generics is ongoing or expired.
Reimbursement
- Reimbursement rates align with CMS guidelines.
- Variability exists across payers, influencing net prices.
Risks and Opportunities
- Risks: Patent challenges, pricing pressure from generics, supply chain disruptions.
- Opportunities: Expansion in emerging markets, formulations enabling multiple uses, and new delivery systems.
Key Takeaways
- The global local anesthetic market, including Bupivacaine, is expanding with steady growth.
- Current prices for NDC 65162-0750 range from $15 to $20 per vial, with downward pressure anticipated due to generic competition.
- Market volume growth could partly offset declining unit prices.
- Price projections suggest a gradual decrease over the next five years, stabilizing around $10-$15 per vial.
FAQs
1. What are the main drivers for price changes in Bupivacaine?
Market competition, raw material costs, regulatory status, and supply chain stability influence pricing.
2. How does patent expiration affect the market?
Patent expiration allows generic manufacturers to enter, increasing competition and reducing prices.
3. Are new formulations impacting the market?
Yes, innovations such as liposomal formulations or extended-release versions can command premium prices and open new market segments.
4. What regional differences affect pricing strategies?
Pricing in North America tends to be higher due to higher reimbursement and purchasing power. Emerging markets offer lower prices but growing volume.
5. How might regulatory changes influence future prices?
Tighter regulations can delay entry of generics, potentially keeping prices higher longer; deregulation or expedited approvals can accelerate price declines.
References
[1] MarketWatch. (2022). Global anesthetic drugs market size. Retrieved from https://www.marketwatch.com
[2] IQVIA. (2022). Generic drugs market share analysis. Retrieved from https://www.iqvia.com
